(238) Radiofrequency Therapy at 448 kHz as a Novel Treatment for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): Results from a Prospective Multicentre Pilot Study

Introduction Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent and disabling condition with unclear pathophysiology and limited therapeutic options. It has a major impact on quality of life and is closely linked to voiding and sexual dysfunction. Monopolar Capacitive/Resistive Radiofrequency (MCRF) therapy at 448 kHz is a non-invasive electrothermal technique that has shown efficacy in several chronic pain conditions, including pelvic pain, however, evidence in CP/CPPS is limited. Objective This multicentre prospective pilot study aimed to assess the safety and effectiveness of 448 kHz MCRF therapy in men with CP/CPPS. Methods A prospective, multicentre, non-randomized study was conducted in men diagnosed with CP/CPPS. Each patient received six sessions of 448 kHz MCRF therapy (INDIBA® AT7 device) over a 6–8 week period. All participants underwent a comprehensive baseline assessment, including physical examination, NIH-CPSI, IPSS, and SHIM questionnaires, blood and urine tests, urine culture (pre- and post-prostatic massage), urethral exudate, and urinary ultrasound to exclude other causes. Follow-up included clinical evaluation and repeat questionnaires at 3 and 6 months. Primary endpoint: change in total NIH-CPSI score. Secondary endpoints: domain-specific NIH-CPSI, IPSS, and SHIM changes. Results Fifty-one men men were included with a mean age of 44.5 ± 11.1 years. The mean baseline NIH-CPSI total score was 25.9 ± 6.0 (Pain 12.1, Urinary 4.9, Quality of life 8.9). At six months, significant improvement was observed in the total NIH-CPSI score, which decreased to 15.8 ± 8.7 (mean change –10.3 ± 9.6; p < 0.0001). All individual domains improved significantly at 3 and 6 months. The mean IPSS score improved from 17.9 ± 7.8 at baseline to 12.6 ± 7.2 at six months (p = 0.0001). In contrast, no significant change was detected in SHIM scores (20.7 vs. 21.3, p = 0.33). No adverse events or therapy-related complications were reported throughout the study. Conclusions MCRF at 448 kHz appears to be a safe and effective treatment for improving pain and quality of life in men with CP/CPPS. These promising findings warrant larger randomized controlled studies to validate efficacy and define its role in future CP/CPPS management algorithms. Disclosure No